Adjusted earnings of $2.17 a share topped the $2.02 analysts were anticipating, according to FactSet. However, second-quarter ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did ...

That growth began last year with Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss.

Eli Lilly’s experimental cholesterol drug doubled patients’ HDL, or good cholesterol, setting the stage for a race between the Indianapolis pharmaceutical company and Merck and Roche Holding ...